| All Releases |
|---|
 |
United Therapeutics Corporation Reports First Quarter 2012 Financial Results
Apr 26, 2012
|
24.1 KB
|
| |
SILVER SPRING, Md., April 26, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the first quarter ended March 31, 2012.
"I am pleased with our strong first quarter results," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "This is an imp...
|
|
|
United Therapeutics Corporation To Announce First Quarter 2012 Financial Results Before Market Open On Thursday, April 26, 2012
Apr 19, 2012
|
7.7 KB
|
| |
SILVER SPRING, Md., April 19, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2012 financial results before market open on Thursday, April 26, 2012.
United Therapeutics will host a half-hour teleconference on Thursday, April 26, 2012, at 9:00 a.m. Eastern Time. The t...
|
|
|
United Therapeutics Files Lawsuit Against Sandoz for Infringement of Remodulin Patents
Mar 15, 2012
|
9.7 KB
|
| |
SILVER SPRING, Md, March 15, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Sandoz Inc. (Sandoz) for infringement of U.S. Patent Nos. 5,153,222, 6,765,117 and 7,999,007 relating to United Therapeutics' product Remodulin...
|
|
|
Oral Treprostinil New Drug Application Accepted by FDA for Review
Feb 21, 2012
|
8.1 KB
|
| |
SILVER SPRING, Md., Feb. 21, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. Food and Drug Administration has accepted for review the new drug application (NDA) for treprostinil diethanolamine sustained release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension. The ND...
|
|
|
United Therapeutics Corporation Reports 2011 Fourth Quarter and Annual Financial Results
Feb 14, 2012
|
68.4 KB
|
| |
Total Annual Revenues of $743.2 million
Annual Earnings per Share of $3.81 per Basic Share or $3.67 per Diluted Share
Annual Earnings Before Non-Cash Charges of $6.36 per Basic Share or $6.12 per Diluted Share
Silver Spring, MD, February 14, 2012: United Therap...
|
|
|
United Therapeutics Corporation to Announce Fourth Quarter and Annual 2011 Financial Results Before Market Open on Tuesday, February 14, 2012
Feb 7, 2012
|
7.7 KB
|
| |
SILVER SPRING, Md., Feb. 7, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2011 financial results before market open on Tuesday, February 14, 2012.
United Therapeutics will host a half-hour teleconference on Tuesday, February 14, 2012, at 9:00 a.m. Easter...
|
|
|
United Therapeutics Receives Paragraph IV Notice Letter for Remodulin
Feb 6, 2012
|
9.1 KB
|
| |
SILVER SPRING, Md., Feb. 6, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced receipt of a Paragraph IV Certification Notice Letter on February 3, 2012 from Sandoz Inc. (Sandoz) advising that Sandoz has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting ap...
|
|
|
Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
Dec 27, 2011
|
13.1 KB
|
| |
SILVER SPRING, Md. and CHERTSEY, England, Dec. 27, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) and its wholly-owned subsidiary, United Therapeutics Europe, Ltd., announced today that the French regulatory agency Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS) has approved intravenous use of Remodulin&#...
|
|
|
United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
Oct 27, 2011
|
27.8 KB
|
| |
SILVER SPRING, Md., Oct. 27, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2011.
"We achieved over $200 million in revenues this quarter, which reflects the continued strength of our core business," remarked Martine Rothblatt, Ph.D., United Ther...
|
|
|
United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
Oct 20, 2011
|
7.7 KB
|
| |
SILVER SPRING, Md., Oct. 20, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2011 financial results before market open on Thursday, October 27, 2011.
United Therapeutics will host a half-hour teleconference on Thursday, October 27, 2011, at 9:00 a.m. Eastern Time. The te...
|
|
|
United Therapeutics Prices Private Offering of Convertible Senior Notes and Announces Concurrent Exercise of Overallotment Option
Oct 12, 2011
|
10.5 KB
|
| |
SILVER SPRING, Md., Oct. 12, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) (the "Company") today announced the pricing of its previously announced offering of $210 million aggregate principal amount of 1.0% convertible senior notes due 2016 to qualified institutional buyers in accordance with Rule 144A under the Securities Act...
|
|
|
United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
Oct 11, 2011
|
10.0 KB
|
| |
SILVER SPRING, Md., Oct. 11, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR - News) (the "Company") today announced that it intends to offer, subject to market and other conditions, $210 million aggregate principal amount of convertible senior notes due 2016 to qualified institutional buyers in accordance with Rule 144A under ...
|
|
|
United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
Oct 10, 2011
|
10.5 KB
|
| |
SILVER SPRING, Md., Oct. 10, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institut...
|
|
|
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
Aug 24, 2011
|
12.9 KB
|
| |
SILVER SPRING, Md., Aug. 24, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmona...
|
|
|
United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
Jul 28, 2011
|
25.0 KB
|
| |
SILVER SPRING, Md., July 28, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended June 30, 2011.
"I'm pleased with the successful unblinding of the FREEDOM-M study this quarter, as well as the very good operating results we achieved," remarked Martine Rothblatt, Ph.D., Un...
|
|
|
United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
Jul 21, 2011
|
7.7 KB
|
| |
SILVER SPRING, Md., July 21, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its second quarter 2011 financial results before market open on Thursday, July 28, 2011.
United Therapeutics will host a half-hour teleconference on Thursday, July 28, 2011, at 9:00 a.m. Eastern Time. The telecon...
|
|
|
FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint
Jun 6, 2011
|
20.5 KB
|
| |
SILVER SPRING, Md., June 6, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary a...
|
|
|
United Therapeutics Corporation Reports First Quarter 2011 Financial Results
Apr 28, 2011
|
23.8 KB
|
| |
SILVER SPRING, Md., April 28, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the first quarter ended March 31, 2011.
"I'm very pleased that we are cruising at a two-thirds of a billion dollar revenue run rate, up almost 30% from a year ago," remarked Martine Rothblatt, Ph.D., United ...
|
|
|
United Therapeutics Corporation to Announce First Quarter 2011 Financial Results Before Market Open on Thursday, April 28, 2011
Apr 21, 2011
|
7.7 KB
|
| |
SILVER SPRING, Md., April 21, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2011 financial results before market open on Thursday, April 28, 2011.
United Therapeutics will host a half-hour teleconference on Thursday, April 28, 2011, at 9:00 a.m. Eastern Time. The telec...
|
|
|
United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
Mar 21, 2011
|
9.0 KB
|
| |
SILVER SPRING, Md., March 21, 2011 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.
FREEDOM-C(2) is a 16-week, multi-center, international, double-blind, randomized, placebo-controlled study of a sustained release oral formulatio...
|
|
|
United Therapeutics' Press Release Archive is furnished solely for historical purposes. Statements made in any release posted here speak only as of the date of such release. We do not undertake any obligation to update any information contained in any release. Our business, financial condition, results of operations and prospects may have changed since the date of any release posted here.
